News >

Alectinib Approved in China for ALK+ NSCLC

Jason M. Broderick @jasoncology
Published: Tuesday, Aug 21, 2018

Dr. Sandra Horning

Sandra Horning, MD
The China National Drug Administration (CNDA) has approved alectinib (Alecensa) for the treatment of patients with ALK-positive, advanced non–small cell lung cancer (NSCLC), according to Roche, the manufacturer of the second-generation ALK inhibitor.

 
China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer. Roche. Published August 20, 2018. Accessed August 21, 2018. https://bit.ly/2BDO2bE.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x